Management guidelines for laboratory exposures to agents of bioterrorism

Journal of Occupational and Environmental Medicine

Volumn 46, Issue 8, 2004, Pages 791-800

  Rusnak, Janice M ^a   Kortepeter, Mark G ^a   Hawley, Robert J ^a,b   Boudreau, Ellen ^a   Aldis, John ^a   Pittman, Phillip R ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b MIDWEST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BOTULINUM TOXIN; CIPROFLOXACIN; DOXYCYCLINE; RICIN; STAPHYLOCOCCUS ENTEROTOXIN; VACCINE;

AEROSOL; ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; BRUCELLA; BURKHOLDERIA PSEUDOMALLEI; CHIKUNGUNYA ALPHAVIRUS; COXIELLA BURNETII; ENCEPHALOMYELITIS; EPIDEMIC ENCEPHALITIS; FRANCISELLA TULARENSIS; HEMORRHAGIC FEVER; HUMAN; INFECTION; INFECTION PREVENTION; JUNIN VIRUS; LABORATORY PERSONNEL; MILITARY MEDICINE; NEEDLESTICK INJURY; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; PLAGUE; POLICY; POSTEXPOSURE PROPHYLAXIS; PRACTICE GUIDELINE; Q FEVER; SMALLPOX; TICK BORNE ENCEPHALITIS; TULAREMIA; VACCINATION; VIRULENCE; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; YELLOW FEVER; YERSINIA PESTIS;

ANTIBIOTIC PROPHYLAXIS; BIOTERRORISM; HUMANS; LABORATORY INFECTION; MILITARY MEDICINE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; QUARANTINE; RISK ASSESSMENT; UNITED STATES; VACCINATION; VACCINES;

ACARI; ALPHAVIRUS; ANTHRAX; BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS); BRUCELLA; BURKHOLDERIA; BURKHOLDERIA PSEUDOMALLEI; CHIKUNGUNYA VIRUS; COXIELLA BURNETII; EQUIDAE; FRANCISELLA TULARENSIS; JUNIN VIRUS; STAPHYLOCOCCUS; VARIOLA VIRUS; WESTERN EQUINE ENCEPHALOMYELITIS VIRUS; YERSINIA; YERSINIA PESTIS;

EID: 4143086056     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jom.0000135536.13097.8a     Document Type: Article

References (43)

1. Page EH, Martinez KF, Seitz TA, Bernard BP, Tepper AL. Update: cutaneous anthrax in a laboratory worker-Texas, 2002. MMWR Morbid Mortal Wkly Rep. 2003;51:482.
2. Gerberding JL. Management of occupational exposures to blood-borne viruses. N Engl J Med. 1995;332:444-451.
3. Holmes GP, Chapman LE, Stewart JA, et al. Guideline for the prevention and treatment of B-virus infections in exposed persons. Clin Infect Dis. 1995;20:421-439.
4. Wedum AG, Barkley WE, Hellman A. Handling of infectious agents. J Am Vet Med Assoc. 1972;161:1557-1567.
5. US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institute of Health. Biosafety in Microbiological and Biomedical Laboratories. 4th ed. Washington, DC: US Government Printing Office; 1999
6. Wedum AG. The Detrick experience as a guide to the probable efficacy of P4 microbiological containment facilities for studies on microbial recombinant DNA molecules. J Am Bio Safety Assoc. 1996;1:7-25.
7. Rusnak JM, Boudreau E, Petit P, Kanesa-Thasan N, Kortepeter M. Management of percutaneous potential exposures to agents considered as bioterrorist threats: Review of USAMRIID's policy and experience from 1990 to 2002. In: Abstracts of the 13th Annual Conference of the Society of Hospital Epidemiology of America, Arlington, VA, 2003 Apr 5-8; Abstract 263. Mt. Royal, (NJ): The Society for Healthcare Epidemiology of America; 2003.
8. Wedum AG. II. Airborne infection in the laboratory. Am J Publ Health. 1964;54:1669-1673.
9. Barbeito MS, Alg RL, Wedum AG. Infectious bacterial aerosol from dropped Petri dish cultures. Am J Med Technol. 1961;27:318-322.
10. Wedum AG. Control of laboratory airborne infections. Bacteriol Rev. 1961;25:210-216.
11. Wedum AG. Prevention of laboratory-acquired infections. Am J Med Technol. 1956;22:311-315.
12. Wedum AG. Defensive aspects of biological warfare. J Am Med Assoc. 1956;162:34-37.
13. Hanel E, Miller OT, Phillips GB, Wedum AG. Laboratory design for study of infectious disease. Am J Publ Health. 1956;46:1102-1113.
14. Reitman M, Wedum AG. Microbiological safety. Publ Health Rep. 1956;71:659-665.
15. Wedum AG. Laboratory safety research with infectious aerosols. Publ Health Rep. 1964;79:619-633.
16. Kruse RH, Wedum AG. Cross infection with eighteen pathogens among caged laboratory animal. Lab Anim Care. 1970;20:541-560.
17. Pike RM, Sulkin SE, Schulze ML. Continuing importance of laboratory-acquired infections. Am J Publ Health. 1965;55:190-199.
18. Burke DS. Immunization against tularemia: analysis of the effectiveness of live Francisells tularensis vacine in prevention of laboratory-acquired tularemia. J Infect Dis. 1977;135:55-60.
19. Pittman PR, Makuch RS, Mangiafico JA, Cannon TL, Gibbs PH, Peters CJ. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine. 1996;14:337-343.
20. Bartelloni PJ, McKinney RW, Duffy TP, Cole FE. An inactivated eastern equine encephalomyelifis vaccine propagated in chick-embryo cell culture. II. Clinical and serologic responses in man. Am J Trop Med Hyg. 1970;19:123-126.
21. Bartelloni PJ. Inactivated western equine encephalomyelitis vaccine propagated in chick embryo cell culture. Clinical and serological evaluation in man. Am J Trop Med Hyg. 1971;20:1446-1449.
22. Pittman PR, Liu CT, Cannon TL, et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine. 1999;18:181-189.
23. Levitt NG, Ramsburh HH, Hasty SE, Repik PM, Cole FE, Lupton H. Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine. 1986;4:157-162.
24. Maiztegui JI, McKee KT, Barrera-Oro JG, et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. J Infect Dis. 1998;177:277-283.
25. Craig SC, Pittman PR, Lewis TE, Rossi CA, Henchal EA, Kuschner RA. An accelerated schedule for tick-borne encephalitis vaccine: the American Military experience in Bosnia. Am J Trop Med Hyg. 1999;61:874-878.
26. Henderson DA, Inglesby TV, Bartlett JG, et al. Smallpox as a biological weapon, medical and public health management. J Am Med Assoc. 1999;281:2127-2137.
27. Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon, medical and public health management J Am Med Assoc. 1999;281:1735-1745.
28. Inglesby TV, Henderson DA, Bartlett JG, et al. Plague as a biological weapon, medical and public health management. J Am Med Assoc. 2000;283:2281-2290.
29. Cieslak TJ, Christopher GW, Kortepeter MG, Rowe JR, Pavlin JA, Culpepper RC. Immunization against potential biological warfare agents. Clin Infect Dis. 2000;20:843-850.
30. Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev. 1982;46:186-194.
31. Hursh S, McNally R, Fanzone J Jr, Mershon M. Staphylococcal enterotoxin B battlefield challenge modeling with medical and non-medical countermeasures. Joppa, MD: Science Applications International Corp; 1995. Technical Report MBDRP-95-2. doses
32. th Infectious Diseases Society of America; Philadelphia, Pennsylvania; 1999 Nov 17-21; Abstract 672. Alexandria, (VA): Infectious Disease Society of America: 1997. Also published in: Clin Infect Dis 1999;29:1083.111
33. th Infectious Diseases Society of America; Philadelphia, Pennsylvania; 1999 Nov 17-21; Abstract 672. Alexandria, (VA): Infectious Disease Society of America: 1997. Also published in: Clin Infect Dis 1999;29:1083.
34. Bell DM, Kozarsky PE, Stephens DS. Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis. 2002;8:222-225.
35. Advisory Committee on Immunization Practices. Use of anthrax vaccine in the United States. MMWR. 2000;49:1-23.
36. Post-exposure anthrax prophylaxis. Med Lett. 2001;43:91-92.
37. Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon, medical and public health management. J Am Med Assoc. 2001;285:2763-2773.
38. Sawyer WD, Dangerfield HG, Hogge AL, Crozier D. Antibiotic prophylaxis and therapy of airborne tularemia. Bacteriol Rev. 1966;30:542-548.
39. Tigertt WD, Benenson AS. Studies on Q fever in man. Trans Assoc Am Phys. 1956;69:98-104.
40. ACIP. Use of anthrax vaccine in response to terrorism: supplemental recommendations of the advisory committee on immunization practices. MMWR. 2002;51:1024-1026.
41. Chapman LE, Mertz CJ, Jolson HM, et al. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther. 1999;4:211-219.
42. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002;55:1-13.
43. Burke DS, Ramsburg HH, Edelman R. Persistence in humans of antibody to subtypes of Venezuelan equine encephalitis (VEE) virus after immunization with attenuated (TC-83) VEE virus vaccine. J Infect Dis. 1977;136:354-359.